Patents by Inventor Zhihua Sui

Zhihua Sui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11957680
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase modulators and use thereof
    Patent number: 11872225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20230226055
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11590132
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 28, 2023
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20220395503
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 15, 2022
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
    Patent number: 11524960
    Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 13, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
  • Pyruvate kinase modulators and use thereof
    Patent number: 11464775
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 11, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
    Publication number: 20220251081
    Abstract: The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 11, 2022
    Inventors: Zenon D. KONTEATIS, Mingzong LI, Samuel K. REZNIK, Jeremy M. TRAVINS, Zhihua SUI
  • PYRUVATE KINASE MODULATORS AND USE THEREOF
    Publication number: 20220233541
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11364240
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • New Organic Compounds
    Publication number: 20220169654
    Abstract: The present application provides MAT2A inhibitor compounds that are useful as therapeutic agents. In some embodiments, the compounds are of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, and X1-X3 are defined herein.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 2, 2022
    Applicant: Servier Pharmaceuticals LLC
    Inventors: Zenon D. KONTEATIS, Mingzong LI, Samuel K. REZNIK, Zhihua SUI
  • AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
    Publication number: 20220144820
    Abstract: The present disclosure provides for compounds according to Formula I and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.
    Type: Application
    Filed: December 27, 2019
    Publication date: May 12, 2022
    Inventors: Zenon D. KONTEATIS, Mingzong LI, Samuel K. REZNIK, Zhihua SUI
  • Inhibitors of cellular metabolic processes
    Patent number: 11325914
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: May 10, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS
    Publication number: 20220127267
    Abstract: Described herein are compounds that regulate pyruvate kinase activity, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R2, L1-L2, U1-U7, m, ring A, and Q are as defined herein.
    Type: Application
    Filed: February 12, 2020
    Publication date: April 28, 2022
    Inventors: Tao Liu, Zhihua Sui, Jingjing Ji
  • AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
    Publication number: 20220098203
    Abstract: The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 31, 2022
    Inventors: Zenon D. KONTEATIS, Mingzong LI, Samuel K. REZNIK, Zhihua SUI, Jeremy M. TRAVINS
  • Benzo-fused heterocyclic derivatives useful as agonists of GPR120
    Patent number: 11254647
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 22, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Zhihua Sui, Nalin L. Subasinghe
  • Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors
    Patent number: 11230526
    Abstract: The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 25, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Mark J. Macielag, Mark Wall, Michael P. Winters, Yue-Mei Zhang, Zhihua Sui
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11040036
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: June 22, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210130371
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Inhibitors of cellular metabolic processes
    Patent number: RE49934
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: April 23, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye